Summary for ARTG Entry:
XALOX RTU oxaliplatin 50mg/10mL concentrated solution for injection vial
ARTG entry for
Medis Pharma Pty Ltd
PO Box 6127,North Sydney, NSW, 2059
ARTG Start Date
Drug Safety Evaluation Branch
Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods
Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered
or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
1. XALOX RTU oxaliplatin 50mg/10mL concentrated solution for injection vial
Single Medicine Product
See Product Information and Consumer Medicine Information for this product
Oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: ,· Adjuvant treatment of stage III (Duke's C) colon cancer after complete
resection of ,the primary tumour ,· Treatment of advanced colorectal cancer
Additional Product information
Glass Type I Clear
Store below 25
Neither child resistant
closure nor restricted
Do not Freeze
Protect from Light
Pack Size/Poison information
(S4) Prescription Only Medicine
Route of Administration
Clear, colourless to slightly yellow solution.
© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior
written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.
Page 1 of
Produced at 29.11.2017 at 11:46:41 AEDT
This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information